Keyword → ARGX

Earlier

argenx Acquires Forte Biosciences for $2.2B at $77 Per Share — 86% Premium Targets First-in-Class Anti-CD122 Antibody FB102

Jul 27, 2026

positive

argenx Acquires Forte Biosciences for $2.2B at $77 Per Share — 86% Premium Targets First-in-Class Anti-CD122 Antibody FB102

argenx announced a $2.2 billion all-cash acquisition of Forte Biosciences at $77 per share, an 86% premium to Forte's volume-weighted average price since its positive Phase 1b vitiligo data on July 9. The deal adds FB102, a first-in-class anti-CD122 antibody with proof-of-concept in vitiligo and celiac disease, to argenx's growing immunology portfolio. The transaction is fully funded from cash and is expected to close in Q3 2026, with argenx hosting an investor call this morning at 8 a.m. ET.

ARGXFBRXXBI
ARGXargenx stockmergerFBRXForte BiosciencesFB102anti-CD122 antibodyimmunology biotech
Read full analysis →

What we cover

STKMRKT publishes daily stock market news covering earnings reports, pre-market movers, Fed policy, macroeconomic data releases, sector trends, and cryptocurrency updates. Every article is written for active traders and long-term investors who need fast, actionable context — not noise.

Market Data

Earnings

Learn

Tools

Page 1 of 1